Status:
COMPLETED
Effect of CP-778,875 on HDL-C in Subjects With Abnormal Lipid Levels and Type 2 Diabetes.
Lead Sponsor:
Pfizer
Conditions:
Dyslipidemia
Eligibility:
All Genders
30-70 years
Phase:
PHASE2
Brief Summary
To assess the effect of CP-778,875 on HDL-C cholesterol in adult subjects with dyslipidemia and type 2 diabetes
Eligibility Criteria
Inclusion
- HDL-C \< or = 45 mg/dL for men and \< or = 55 mg/dL for women
- Triglycerides between 150-500 mg/dL
- Fasting Plasma Glucose 140-240 mg/dL
Exclusion
- Known cardiovascular, carotid, or peripheral vascular disease
Key Trial Info
Start Date :
July 1 2006
Trial Type :
INTERVENTIONAL
End Date :
June 1 2007
Estimated Enrollment :
84 Patients enrolled
Trial Details
Trial ID
NCT00326326
Start Date
July 1 2006
End Date
June 1 2007
Last Update
May 7 2009
Active Locations (31)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Anniston, Alabama, United States, 36207
2
Pfizer Investigational Site
Huntsville, Alabama, United States, 35801
3
Pfizer Investigational Site
Greenbrae, California, United States, 94904
4
Pfizer Investigational Site
Los Angeles, California, United States, 90057